Barclays Issues Positive Forecast for Edwards Lifesciences (NYSE:EW) Stock Price

Edwards Lifesciences (NYSE:EW) had its price target hoisted by Barclays from $110.00 to $120.00 in a research note released on Thursday,Benzinga reports. The brokerage currently has an overweight rating on the medical research company’s stock.

Several other equities analysts have also weighed in on EW. UBS Group reaffirmed a “buy” rating and set a $110.00 target price (up from $90.00) on shares of Edwards Lifesciences in a report on Thursday, October 8th. Wall Street Zen lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, October 31st. Mizuho set a $120.00 price objective on shares of Edwards Lifesciences in a report on Thursday. Piper Sandler reissued an “overweight” rating and set a $115.00 target price (up from $101.00) on shares of Edwards Lifesciences in a research note on Thursday. Finally, Argus upped their price target on Edwards Lifesciences from $105.00 to $115.00 and gave the stock a “buy” rating in a report on Friday, August 21st. Twenty-three analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average target price of $108.88.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $100.70 on Thursday. Edwards Lifesciences has a 52-week low of $74.66 and a 52-week high of $104.17. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The stock has a market cap of $57.99 billion, a PE ratio of 56.90, a price-to-earnings-growth ratio of 2.60 and a beta of 0.85. The business has a 50-day simple moving average of $88.68 and a 200-day simple moving average of $85.69.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Wednesday, November 4th. The medical research company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.74 by $0.06. The firm had revenue of $1.72 billion for the quarter, compared to analyst estimates of $1.68 billion. Edwards Lifesciences had a return on equity of 16.25% and a net margin of 15.30%. Edwards Lifesciences’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same period last year, the company earned $0.67 earnings per share. On average, equities analysts expect that Edwards Lifesciences will post 3.00 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 544 shares of the firm’s stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $91.06, for a total value of $49,536.64. Following the transaction, the senior vice president directly owned 14,868 shares of the company’s stock, valued at approximately $1,353,880.08. This trade represents a 3.53% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Annette Brüls sold 2,644 shares of Edwards Lifesciences stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the sale, the vice president owned 17,984 shares in the company, valued at approximately $1,618,200.32. The trade was a 12.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 5,045 shares of company stock valued at $451,596 over the last 90 days. Corporate insiders own 0.31% of the company’s stock.

Institutional Trading of Edwards Lifesciences

A number of institutional investors have recently made changes to their positions in the company. Maryland State Retirement & Pension System lifted its holdings in Edwards Lifesciences by 9.3% in the 3rd quarter. Maryland State Retirement & Pension System now owns 34,128 shares of the medical research company’s stock valued at $2,946,000 after purchasing an additional 2,896 shares in the last quarter. Ritholtz Wealth Management grew its holdings in shares of Edwards Lifesciences by 91.6% during the third quarter. Ritholtz Wealth Management now owns 15,148 shares of the medical research company’s stock worth $1,308,000 after buying an additional 7,241 shares in the last quarter. Jacobi Capital Management LLC purchased a new stake in shares of Edwards Lifesciences during the third quarter worth $32,000. Jefferies Financial Group Inc. raised its position in shares of Edwards Lifesciences by 649.1% in the third quarter. Jefferies Financial Group Inc. now owns 296,800 shares of the medical research company’s stock valued at $25,620,000 after buying an additional 257,180 shares during the last quarter. Finally, First Command Advisory Services Inc. raised its position in shares of Edwards Lifesciences by 261.5% in the third quarter. First Command Advisory Services Inc. now owns 2,686 shares of the medical research company’s stock valued at $232,000 after buying an additional 1,943 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Key Edwards Lifesciences News

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards beat Q3 estimates, reporting adjusted EPS of $0.80 versus $0.74 expected and revenue of $1.72 billion, up about 11% year over year. It raised its full-year sales outlook and set adjusted EPS guidance of $2.97–$3.05. TAVR sales grew 8.8%, while transcatheter mitral and tricuspid therapies (TMTT) grew 45.6%, supporting the growth outlook. Q3 earnings and outlook
• Positive Sentiment: New PROGRESS Trial data found TAVR performed better than active surveillance for at-risk patients with moderate aortic stenosis, including fewer combined death or heart-failure events and better quality-of-life measures. The findings could support broader future use, though they do not by themselves establish a change in treatment or reimbursement. PROGRESS Trial data
• Positive Sentiment: Analysts responded favorably to the results: UBS raised its target to $118 and JPMorgan to $120, while other firms also increased targets and several upgraded the shares. The revisions signal improved expectations, but are analyst opinions rather than guaranteed returns. UBS price-target increase JPMorgan price-target increase
• Negative Sentiment: Edwards’ CEO acknowledged that more competition is coming in TAVR, a potential challenge to market share and growth. CEO comments on TAVR competition

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.